Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)

Shunichi Sugawara, Masashi Kondo, Toshihide Yokoyama, Toru Kumagai, Makoto Nishio, Koichi Goto, Kazuhiko Nakagawa, Takashi Seto, Nobuyuki Yamamoto, Kentarou Kudou, Takayuki Asato, Pingkuan Zhang, Yuichiro Ohe

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology